{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Astrazeneca Pharma India Ltd
Is Astrazeneca Phar technically bullish or bearish?
As of November 7, 2025, the trend is mildly bullish, supported by positive MACD readings and moving averages, despite mixed signals from the KST and recent price declines, with strong long-term returns over 3 and 5 years.
Astrazeneca Pharma India Shows Strong Financial Performance Amid Mixed Technical Signals
Astrazeneca Pharma India has recently experienced a change in its evaluation, influenced by shifts in technical indicators. The company has shown strong financial performance, with a year-to-date return of 23.77% and a notable profit growth of 35.70% in the last six months, outperforming the BSE500 index consistently.
AstraZeneca Pharma India Faces Mixed Technical Trends Amid Strong Long-Term Performance
AstraZeneca Pharma India has recently revised its evaluation amid current market dynamics, with its stock priced at 9,078.70. Over the past year, it has achieved a return of 20.97%, significantly outperforming the Sensex. The technical outlook presents mixed signals, indicating cautious optimism in its performance.
How has been the historical performance of Astrazeneca Phar?
Astrazeneca Phar has shown significant growth in net sales, reaching 1,716.29 Cr in March 2025, up from 1,002.97 Cr in March 2023, despite a decline in profit margins and earnings per share. Total assets and liabilities increased to 1,476.56 Cr, while cash and cash equivalents rose to 536.70 Cr, indicating improved cash flow.
Is Astrazeneca Phar technically bullish or bearish?
As of November 7, 2025, the trend is mildly bullish, supported by weekly MACD and KST indicators, but caution is advised due to mixed signals from the monthly KST and RSI.
Are Astrazeneca Phar latest results good or bad?
AstraZeneca Pharma India's Q2 FY26 results show strong revenue growth of 35.81% year-on-year, but net profit declined by 4.15%, indicating pressure on margins. While the company demonstrates solid operational capabilities, investors should monitor its ability to improve profitability alongside revenue growth.
Is Astrazeneca Phar technically bullish or bearish?
As of November 7, 2025, the trend has shifted to mildly bullish, supported by positive MACD signals and mixed indicators from Bollinger Bands and moving averages, suggesting caution despite some positive momentum.
AstraZeneca Pharma India Q2 FY26: Strong Revenue Growth Masks Profitability Concerns
AstraZeneca Pharma India Ltd. delivered a mixed performance in Q2 FY26, with robust revenue expansion overshadowed by margin compression and a sequential decline in profitability. The pharmaceutical major reported net sales of ₹526.31 crores for the quarter ended June 2025, marking a healthy 9.54% quarter-on-quarter increase and an impressive 35.81% year-on-year surge. However, net profit stood at ₹55.83 crores, declining 4.15% sequentially from ₹58.25 crores in Q1 FY26, though still recovering substantially from the loss of ₹11.79 crores recorded in the corresponding quarter last year.
Astrazeneca Pharma India Shows Strong Financial Growth and Positive Technical Trends
Astrazeneca Pharma India has recently experienced a score adjustment, reflecting changes in its technical trends. The company reported a 39.08% increase in profit after tax, reaching Rs 118.57 crore, and achieved record net sales of Rs 526.31 crore, highlighting its strong market performance and efficiency.
Is Astrazeneca Phar technically bullish or bearish?
As of October 28, 2025, the trend has shifted to bullish, supported by strong indicators like bullish MACD and Bollinger Bands, although the KST and OBV show some mixed signals.
AstraZeneca Pharma India's Technical Trends Indicate Strong Market Position Amid Volatility
AstraZeneca Pharma India has recently revised its evaluation, reflecting its strong market position. The stock has shown impressive growth over the past year, significantly outperforming the Sensex. Technical indicators present a generally positive outlook, although some caution is advised in the short term due to mixed signals.
How has been the historical performance of Astrazeneca Phar?
Astrazeneca Phar has shown strong financial growth, with net sales increasing from 728.29 Cr in Mar'19 to 1,716.29 Cr in Mar'25, and operating profit rising from 87.58 Cr to 294.60 Cr in the same period. However, profit before tax peaked in Mar'24 and then declined, while total assets grew significantly from 691.72 Cr to 1,476.56 Cr.
Is Astrazeneca Phar technically bullish or bearish?
As of 20 October 2025, the trend is mildly bullish with supportive signals from MACD and Bollinger Bands, but mixed indicators from KST and Dow Theory suggest caution.
Is Astrazeneca Phar technically bullish or bearish?
As of October 17, 2025, AstraZeneca's technical trend has shifted to bullish, supported by strong MACD indicators and daily moving averages, despite mixed signals from KST and OBV.
AstraZeneca Pharma India Shows Positive Technical Trends Amid Market Resilience
AstraZeneca Pharma India has shown resilience in the pharmaceuticals sector, with a year-to-date return of 24.68%, significantly outperforming the Sensex. The stock has increased over the past year by 19.96%, reflecting strong market positioning and growth, despite mixed technical indicators.
Is Astrazeneca Phar technically bullish or bearish?
As of October 17, 2025, AstraZeneca's stock trend has shifted to bullish, supported by strong indicators like a bullish MACD and moving averages, despite some mild bearish signals from KST and OBV.
Is Astrazeneca Phar technically bullish or bearish?
As of 17 October 2025, the technical trend is bullish, supported by strong indicators like a bullish MACD and moving averages, despite some mild bearishness in KST and OBV, with the stock up 24.68% year-to-date, outperforming the Sensex.
Astrazeneca Pharma India Shows Mixed Technical Outlook Amid Strong Performance Metrics
Astrazeneca Pharma India has recently experienced a change in evaluation, influenced by its technical trends. The company has shown strong performance with significant returns year-to-date and over the past year, alongside positive financial metrics and consistent growth in net sales and profit after tax.
Is Astrazeneca Phar technically bullish or bearish?
As of 13 October 2025, the trend is mildly bullish with positive momentum from MACD and Bollinger Bands, but mixed signals from KST and OBV suggest some caution.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
